Winston Tan, M.D., is focused on translating basic science principles into tangible treatment options for patients with cancer.
He is interested in the importance of molecular pathways, such as those related to the estrogen receptor, vascular endothelial factor and HER-2 receptor, in the pathogenesis and therapy of cancer.
- Developing novel hormonal strategies to abrogate the pathway of resistance in breast cancer, prostate cancer and bladder cancer
- Identifying molecular markers that will predict response and toxicity to targeted treatment
- Identifying and developing novel targets for kidney cancer, including predictors of treatment response and resistance
Significance to patient care
The development of novel targets of therapy would lead to oral and less toxic treatments for cancer. These treatments would also be able to lead to meaningful improvement of quality of life, prolongation of the time to cancer progression and hopefully improved survival.
- Board Member, Florida Society of Clinical Oncology
- Fellow, American College of Physicians
- Member, Membership Committee, American Society of Clinical Oncology